Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence. [Wikipedia]
Under the urologist’s care, she was prescribed solifenacin succinate (5 mg/day) for 3 weeks, Oxybutynin chloride (5 mg/day) for 3 weeks, Fesoterodine fumarate (8 mg/day) for 3 months, and propiverine hydrochlroride (20 mg/day) for 4 weeks.
However, whereas the MPA has delegated responsibility to self-regulatory bodies to the extent that the MPA will itself submit complaints to the NBL, and will typically respect decisions even if they are contrary to the agency’s own view (see the Vesicare example in Table 5), the MHRA at least seems to retain a few more functions by comparison.
She was under treatment with Paroxetine and solifenacin succinate.
A fixed-dose combination (FDC) tablet of Tamsulosin oral controlled absorption system (OCAS) 0.4 mg and solifenacin succinate 6 mg (Vesomni™, Astellas Pharma Europe BV, Leiden, the Netherlands) has been recently authorized for use in men with moderate-to-severe storage symptoms and voiding symptoms associated with BPH, not adequately responding to treatment with monotherapy.
A 4-week course of solifenacin succinate treatment in women with OAB seemed to have no clinically significant effect on intraocular pressure, but further larger studies are needed to determine the effect of anticholinergics on anterior chamber parameters and to evaluate their safety in glaucoma patients [61, 62].
Complaining of severe symptoms, the patient had been treated with various anticholinergic agents (Cetriprin, Detrusitol, and Vesicare) with only periodical relief.
Patients in group I (n = 84) received no treatment (control group) (C group), patients in group II (n = 85) received a daily oral dose of Tamsulosin 0.4 mg (T group), patients in group III (n = 84) received solifenacin succinate 10 mg (S group), and patients in group IV (n = 85) received a combination of the two medications once daily (T/S group).
We added an anticholinergic, solifenacin 5 mg (Vesicare, Astellas Pharm Manufacturing Inc., Tokyo, Japan), to low-dose triple therapy and investigated the findings after administration for 8 weeks.
A randomized, double-blind, active and placebo-controlled, multicenter dose-ranging study is currently underway to evaluate the efficacy, safety, and tolerability of six dose combinations of solifenacin succinate and mirabegron compared to mirabegron and solifenacin succinate monotherapies for treating overactive bladder.
On the other hand, three new anticholinergic agents, solifenacin succinate, Tolterodine tartrate, and imidafenacin, were successively approved and marketed in recent years.